ClinicalTrials.gg
RecruitingNCT07484633PEBBLEUpdated Nov 6, 2026

A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients

A Phase 4 interventional study of Extended infusion time of the following beta-lactam: meropenem and Short-term infusion time of the following beta-lactam: meropenem in Infection, Sepsis and NICU, sponsored by Semmelweis University. Recruiting at 2 sites in Hungary. Open to participants aged 0 Hours to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionSepsisRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sepsis
Why
  1. The study's listed conditions name Sepsis, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Semmelweis University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
0 Hours to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Sepsis with a site in Hungary — 4 open to participants now, 4 under way, none of them phase 3. Sepsis · Hungary.

Planned enrollment
10th of 16
110 · median 130
Started
2026
with 2 others
Phase 4
3 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
3 of 22
Semmelweis University

Among the 22 studies in Sepsis with a site in Hungary, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 21st registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

4 of the 22 studies in Sepsis with a site in Hungary are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 0 Hours to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sepsis with a site in Hungary, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.

The main question it aims to answer is:

Is the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.

Participants will:

  • be given the required antibiotic drug in a 3-hour-long or in a 0.5 hour-long infusion.
  • be examined to make sure their blood drug levels are correct. This will require two blood tests.
  • be treated according to routine care and have examinations and blood tests performed.
Read the detailed description

Treatment begins with a short, intermittent infusion of antibiotics. If the patient meets study criteria, randomisation must occur within 24 hours. Prior to enrolment, written informed consent or a declaration of contribution must be signed by the legal guardian and, where age-appropriate, the patient.

Plans for the collection and laboratory evaluation of biological samples:

Per protocol:

This study involves collecting blood samples (200 µl per sample) to monitor drug levels, with each sample identified by the patient's assigned PIN (Personal Identification Number). To ensure measurements reflect steady-state conditions, samples must be collected at least 48 hours after the first post-allocation dose and immediately prior to the next scheduled dose (trough or minimum level). Analysis of free (unbound) drug concentrations is performed via High-Performance Liquid Chromatography (HPLC) with specific absorbance detection for meropenem (290 nm), piperacillin (252 nm), tazobactam (210 nm), and cefepime (263 nm); ceftriaxone is measured using Liquid Chromatography-Mass Spectrometry (LC-MS).

For evaluating the drug levels:

Pathogen minimal inhibitory concentration (MIC) values will be sourced directly from the microbiology laboratory when available; otherwise, values will be retrieved from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) database. In place of a measured MIC, the epidemiological cut-off value (ECOFF)-representing the upper MIC limit for wild-type, non-resistant bacteria-may be used. For empirical dosing where no specific pathogen is identified, the highest MIC for antibiotic-susceptible bacteria will be applied to account for a worst-case scenario.

Standard care:

Routine laboratory assessments-including a complete blood count (CBC) and blood chemistry tests-will be conducted at enrolment and daily thereafter. To ensure accuracy, samples must be analysed within 1-2 hours of collection. Baseline data will include inflammatory markers (C-reactive protein [CRP], procalcitonin [PCT]), hematological parameters (white blood cell count [WBC], platelet count), liver function (liver enzymes and total/direct bilirubin), and serum creatinine. Additionally, clinical severity will be assessed using Paediatric Index of Mortality 3 (PIM-3), Paediatric Risk of Mortality III (PRISM III), and Paediatric Logistic Organ Dysfunction 2 (PELOD 2) scores. While all patients require a pre-antibiotic blood culture, those with negative cultures will be excluded from the microbiological eradication analysis.

In cases where microbiological cultures are negative, the clinician will diagnose infection based on clinical signs and symptoms. These signs and symptoms will also be examined when assessing the clinical response outcome.

Signs of infection may include elevated acute phase proteins (CRP > 10 mg/L or PCT > 0.5 µg/L or WBC > 10,000 /µL), or infection/inflammation confirmed by imaging and any clinical signs (fever > 37.5 °C core temperature or haemodynamic instability - need for inotropic or vasopressor therapy or abnormal blood gas values (normal arterial blood gas values: pH=7.35-7.45, PaO2=80-100 mmHg, PCO2=35-45 mmHg, [HCO3-]=22-28 mEq/L and lactate\<3 mmol/L; normal venous blood gas values: pH=7.31-7.41, PvO2=35-45 mmHg, PCO2=41-51 mmHg, [HCO3-]=22-28 mEq/L and lactate\<3 mmol/L; normal capillary blood gas values: pH=7.35-7.45, PCO2=35-45 mmHg, [HCO3-]=22-28 mEq/L) or respiratory failure or neurological signs or enteral feeding intolerance.

Criteria for discontinuation or modification of designated interventions:

If blood samples reveal sub-therapeutic antibiotic levels (underexposure), dosing must be adjusted by increasing the dose or the frequency of administration. All adjustments must be documented. Patients requiring these changes will remain in their originally assigned study arm for analysis under the modified intention-to-treat (mITT) population; crossover between study arms is strictly prohibited. In the event of clinician-reported adverse events, the Steering Committee (SC) will determine whether the antibiotic should be discontinued.

If β-lactam therapy must be changed due to clinical deterioration or antibiotic resistance, and the new antibiotic is also a study β-lactam (meropenem, piperacillin/tazobactam, cefepime, or ceftriaxone), the patient remains in the assigned arm (extended infusion [EI] or short-term infusion [SI]) and is not excluded.

All patients are followed for 30 days post-allocation or until discharge or death. For patients discharged before the 30-day mark, a telephone follow-up will be conducted on day 30 to evaluate their clinical status.

03

Conditions studied

  • Infection
  • Sepsis
  • NICU
  • PICU
  • Beta Lactams

Browse trials for

04

In context

Sepsis Reclassified

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 110 is close to the median of 102 across 1,169 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.

Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
0 Hours to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination;
  • who are receiving β-lactams including meropenem, piperacillin/tazobactam, cefepime and ceftriaxone;
  • who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration;
  • written consent of the parent or guardian is obtained.

Exclusion criteria

Exclusion Criteria:

  • palliative care patients;
  • patients participating in other drug trials;
  • patients with impaired renal function if dosing modification is required (estimated [eGFR]\<50 mL/min/1.73m2 for meropenem, cefepime, and piperacillin/tazobactam; eGFR\<10 mL/min/1.73m2 for ceftriaxone);
  • patients undergoing plasmapheresis (TPE);
  • patients undergoing extracorporeal therapy (continuous kidney replacement therapy [CKRT] or extracorporeal membrane oxygenation [ECMO]);
  • β-lactam allergy;
  • patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours;
  • pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    pediatric patients, short-term infusion (P, SI) and neonatal patients, short-term infusion (N, SI)

    subset P: 28 days - 17 years subset N: term or pre-term infants \< 28 days of post-natal age, or PMA\* \< 44 weeks \*postmenstrual age

    Drug: Short-term infusion time of the following beta-lactam: meropenem · Drug: Short-term infusion time of the following beta-lactam: piperacillin/tazobactam · Drug: Short-term infusion time of the following beta-lactam: cefepime · Drug: Short-term infusion time of the following beta-lactam: ceftriaxone

  • Experimental
    pediatric patients, extended infusion (P, EI) and neonatal patients, extended infusion (N, EI)

    subset P: 28 days - 17 years subset N: term or pre-term infants \< 28 days of post-natal age, or PMA\* \< 44 weeks \*postmenstrual age

    Drug: Extended infusion time of the following beta-lactam: meropenem · Drug: Extended infusion time of the following beta-lactam: piperacillin/tazobactam · Drug: Extended infusion time of the following beta-lactam: cefepime · Drug: Extended infusion time of the following beta-lactam: ceftriaxone

Interventions

  • DrugExtended infusion time of the following beta-lactam: meropenem

    Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugShort-term infusion time of the following beta-lactam: meropenem

    Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugExtended infusion time of the following beta-lactam: piperacillin/tazobactam

    Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g piperacillin/tazobactam per dose) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugExtended infusion time of the following beta-lactam: cefepime

    Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- cefepime (CFP): 30-50 mg/kg q8h or q12h (\>1 month: 30 mg/kg every 8-12 hours, 2 months-17 years (bodyweight up to 41 kg): 50 mg/kg every 8-12 hours (max. 2 g per dose; increased dose \[q8h\] used for severe infection and febrile neutropenia) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugExtended infusion time of the following beta-lactam: ceftriaxone

    Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugShort-term infusion time of the following beta-lactam: piperacillin/tazobactam

    Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g piperacillin/tazobactam per dose) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugShort-term infusion time of the following beta-lactam: cefepime

    Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- cefepime (CFP): 30-50 mg/kg q8h or q12h (\>1 month: 30 mg/kg every 8-12 hours, 2 months-17 years (bodyweight up to 41 kg): 50 mg/kg every 8-12 hours (max. 2 g per dose; increased dose \[q8h\] used for severe infection and febrile neutropenia) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

  • DrugShort-term infusion time of the following beta-lactam: ceftriaxone

    Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

07

What researchers measure

Primary outcomes

  1. Proportion of patients achieving PK/PD index: 100% fT>MIC (Ctrough >MIC)

    In critically ill patients, it is recommended to maintain plasma levels 1-4 times higher than the minimal inhibitory concentration (MIC) of the bacterium isolated throughout the dosing interval (100% fT\>1-4×MIC). The primary outcome for the study will be the proportion of patients achieving therapeutic and optimal drug exposure, defined as plasma concentrations above the MIC for 100% of the dosing interval. Trough plasma concentration levels should be measured. The pharmacokinetic-pharmacodynamic (PK/PD) index used is 100% fT\>MIC (Ctrough \>MIC).

    Time frame: two times >48 hours after initiation of antibiotic treatment according to the treatment allocation

Secondary outcomes

  1. Proportion of patients achieving PK/PD index: 100% fT>4xMIC (Ctrough >4xMIC)

    In critically ill patients, it is recommended to maintain plasma levels 1-4 times higher than the MIC (minimal inhibitory concentration) of the bacterium isolated throughout the dosing interval (100% fT\>1-4×MIC). Trough plasma concentration levels should be measured. The pharmacokinetic-pharmacodynamic (PK/PD) index used is 100% fT\>4xMIC (Ctrough \>4xMIC).

    Time frame: two times >48 hours after initiation of antibiotic treatment according to the treatment allocation

  2. Time to normalisation of C-reactive protein (CRP)

    It shows how many days it takes for CRP to return to normal (\<10 mg/L).

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  3. Time to normalisation of procalcitonin (PCT)

    It shows how many days it takes for PCT to return to normal (\<0.5 µg/L).

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  4. Time to normalisation of white blood cells (WBC)

    It shows how many days it takes for WBC to return to normal (\<10,000 /µl).

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  5. Microbiological eradication rate

    Blood culture must be taken from each patient before starting antibiotic treatment. Additional samples should be taken according to the regimen mentioned below.

    Time frame: On day 0 before initiation of antibiotic treatment and on days 2, 3 and 5 after initiation of antibiotic treatment

  6. Clinical response

    Resolution (or clinical success): disappearance of all signs and symptoms related to the infection. * Improvement: a marked or moderate reduction in the severity and/or number of signs and symptoms of infection. * Failure: reduction in signs and symptoms of infection is not sufficient to meet the criteria for improvement, which encompasses outcomes such as death or cases where evaluation was not feasible for any reason.

    Time frame: Each day from enrollment to the end of treatment (maximum 30 days).

  7. Time to clinical success or resolution

    It shows how many days it takes to achieve clinical success or resolution.

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  8. Treatment failure

    Number of patients for whom the β-lactam antibiotic therapy had to be discontinued due to clinical deterioration and/or antibiotic resistance. If the newly initiated β-lactam is also among the study β-lactams (meropenem, piperacillin/ tazobactam, cefepime, and ceftriaxone), the patient remains in the originally assigned treatment arm (EI or SI).

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  9. Duration of the antibiotic therapy

    It shows how many days the antibiotic had to be administered.

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  10. Length of PICU/NICU stay in hours

    It shows how many hours passed from admission to discharge. PICU=Pediatric Intensive Care Unit NICU=Neonatal Intensive Care Unit

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  11. Length of hospital stay (LOS) in days

    It shows how many days passed from admission to discharge.

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  12. All-cause mortality

    The total number of deaths from any cause.

    Time frame: From enrollment to the end of treatment (maximum 30 days).

  13. Adverse events (AEs)

    Definition of adverse event: any harmful, undesirable, potentially severe, or life-threatening effects occurring during or after the administration of the antibiotics proposed in this study. They will be collected in a form where all AEs are listed according to the Summary of Product Characteristics (SmPCs).

    Time frame: Each day from enrollment to the end of treatment (maximum 30 days).

08

Study locations

2 of 2 sites recruiting
  • Pediatric Center (Bókay Street Department), Semmelweis University
    Budapest, 1083, Hungary
    Recruiting
  • Pediatric Center (Tűzoltó Street Department), Semmelweis University
    Budapest, 1094, Hungary
    Recruiting
09

References and documents

Publications

  • Andre P, Diezi L, Dao K, Crisinel PA, Rothuizen LE, Chtioui H, Decosterd LA, Diezi M, Asner S, Buclin T. Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance! Front Pediatr. 2022 Jan 5;9:768438. doi: 10.3389/fped.2021.768438. eCollection 2021. PubMed 35083184 ↗
  • Van Der Heggen T, Dhont E, Willems J, Herck I, Delanghe JR, Stove V, Verstraete AG, Vanhaesebrouck S, De Paepe P, De Cock PAJG. Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome. Pediatr Crit Care Med. 2022 Jul 1;23(7):e309-e318. doi: 10.1097/PCC.0000000000002951. Epub 2022 Apr 15. PubMed 35426861 ↗
  • O'Keefe K, Denny KJ, Le Marsney R, McCullough J, Gilholm P, Budai KA, Beranger A, Lodi C, Obeidat M, Ragonnet G, Wacharachaisurapol N, Roberts JA, Gibbons KS, Raman S. Prolonged Versus Intermittent Beta-Lactam Antibiotic Infusions in Paediatric Critical Care: A Systematic Review and Meta-Analysis. J Paediatr Child Health. 2026 Feb;62(2):160-170. doi: 10.1111/jpc.70275. Epub 2025 Dec 27. PubMed 41454710 ↗
  • Briand A, Bernier L, Pincivy A, Roumeliotis N, Autmizguine J, Marsot A, Metras ME, Thibault C. Prolonged Beta-Lactam Infusions in Children: A Systematic Review and Meta-Analysis. J Pediatr. 2024 Dec;275:114220. doi: 10.1016/j.jpeds.2024.114220. Epub 2024 Aug 2. PubMed 39097265 ↗
  • Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14. PubMed 24429437 ↗
  • Zhou P, Zhang Y, Wang Z, Ying Y, Xing Y, Tong X, Zhai S. Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis. Antibiotics (Basel). 2021 Sep 9;10(9):1088. doi: 10.3390/antibiotics10091088. PubMed 34572670 ↗
  • Hartman SJF, Bruggemann RJ, Orriens L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature. Clin Pharmacokinet. 2020 Feb;59(2):173-205. doi: 10.1007/s40262-019-00813-w. PubMed 31432468 ↗
  • Cies JJ, Moore WS 2nd, Enache A, Chopra A. beta-lactam Therapeutic Drug Management in the PICU. Crit Care Med. 2018 Feb;46(2):272-279. doi: 10.1097/CCM.0000000000002817. PubMed 29112080 ↗
  • Imburgia TA, Kussin ML. A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients. J Pediatr Pharmacol Ther. 2022;27(3):214-227. doi: 10.5863/1551-6776-27.3.214. Epub 2022 Mar 21. PubMed 35350159 ↗
  • Budai KA, Timar AE, Obeidat M, Mate V, Nagy R, Harnos A, Kiss-Dala S, Hegyi P, Garami M, Hanko B, Lodi C. Extended infusion of beta-lactams significantly reduces mortality and enhances microbiological eradication in paediatric patients: a systematic review and meta-analysis. EClinicalMedicine. 2023 Nov 2;65:102293. doi: 10.1016/j.eclinm.2023.102293. eCollection 2023 Nov. PubMed 38021371 ↗

Individual participant data

Plan to share: Yes — After publication, the IPD that underlie the results will be available upon request in encrypted form, subject to approval by the corresponding author.

Time frame: Data will be available immediately following publication with no end date.

Access criteria: Data will be made available to investigators who submit a request for data access for specific aims, subject to approval by the corresponding author. A proposal that describes planned analyses must be submitted to the the corresponding author.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.

Of 65 non-industry phase 4 interventional studies under Sepsis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 23 months is close to that.

Counting every sponsor, half of 66 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Apr 2026 → Sep 2026, primary completion Apr 2028 → Aug 2028 and completion Apr 2028 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 20, 2026
StartActual
Sep 1, 2026was Apr 2026
Primary completionEst.
Aug 31, 2028was Apr 2028
CompletionEst.
Aug 31, 2028was Apr 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Pediatric Center (Bókay Street Department), Semmelweis University · Budapest, Hungaryno status→Recruiting
  • Pediatric Center (Tűzoltó Street Department), Semmelweis University · Budapest, Hungaryno status→Recruiting
Nov 6, 2026
Start date
Apr 2026→Sep 1, 2026 (actual)
Nov 6, 2026
Primary completion
Apr 2028→Aug 31, 2028
Nov 6, 2026
Study completion
Apr 2028→Aug 31, 2028
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Pediatric Center (Tűzoltó Street Department), Semmelweis University · Budapest, HungaryContact added b•••@semmelweis.hu · •••2915
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Pediatric Center (Bókay Street Department), Semmelweis University · Budapest, Hungaryno status→Recruiting
    • Pediatric Center (Tűzoltó Street Department), Semmelweis University · Budapest, Hungaryno status→Recruiting
    Start date Apr 2026→Sep 1, 2026 (now actual)
    Primary completion Apr 2028→Aug 31, 2028
    Study completion Apr 2028→Aug 31, 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Pediatric Center (Tűzoltó Street Department), Semmelweis University · Budapest, HungaryContact added b•••@semmelweis.hu · •••2915
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07484633
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Sep 1, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Kinga Anna Budai
Contact
budai.kinga@semmelweis.hu
+36206632915

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion